Atrion (NASDAQ:ATRI) Now Covered by StockNews.com

StockNews.com started coverage on shares of Atrion (NASDAQ:ATRI) in a report released on Thursday morning. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Price Performance

NASDAQ:ATRI opened at $457.65 on Thursday. The company has a market capitalization of $805.46 million, a PE ratio of 43.01 and a beta of 0.68. The firm’s 50-day moving average price is $456.19 and its 200-day moving average price is $414.57. Atrion has a 1-year low of $274.98 and a 1-year high of $575.88.

Atrion (NASDAQ:ATRI) last posted its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The business had revenue of $47.33 million for the quarter.

Atrion Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Friday, June 14th were issued a dividend of $2.20 per share. This represents a $8.80 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date of this dividend was Friday, June 14th. Atrion’s dividend payout ratio (DPR) is currently 82.71%.

Institutional Investors Weigh In On Atrion

Institutional investors and hedge funds have recently modified their holdings of the stock. Copeland Capital Management LLC boosted its stake in Atrion by 56.4% during the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 31 shares during the period. Quadrant Capital Group LLC bought a new position in Atrion in the fourth quarter worth about $36,000. Harbor Investment Advisory LLC increased its holdings in shares of Atrion by 33.1% during the fourth quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after acquiring an additional 47 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Atrion during the first quarter valued at about $91,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Atrion by 592.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 231 shares in the last quarter. Institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.